BioMarin Pharmaceutical Inc. ( BMRN) TD Cowen 46th Annual Health Care Conference March 4, 2026 10:30 AM EST ...

Welcome to Pharmaceutical Executive Daily, your quick briefing on the top news shaping the pharmaceutical and life sciences industry. In today’s Pharmaceutical Executive Daily, ...

TrialAssure announced today announced the launch of its AI in Medical Writing Certification (AIMWC) Program, a new ...

Karthik Sankaranarayanan trained in two quite different scientific subfields as a graduate student and as a postdoctoral ...

Biotech company BioMarin Pharmaceutical (NASDAQ:BMRN) reported Q4 CY2025 results , with sales up 17% year on year to $874.6 ...

AI is rewriting biotech’s commercial playbook—cutting waste, shrinking teams, and giving first‑time drugmakers a faster, smarter path to launch.

X4 Pharmaceuticals is a BUY, driven by a funded Phase 3 trial, current product pipeline, and a strong cash position extending ...

A decade ago, more than 63% of the pharmaceutical giant's revenue was tied up in one drug -- Humira. Granted, it was the top-selling drug in the world at the time. But despite the 130 patents it ...

As the pharmaceutical industry continues to evolve in the wake of pandemic-driven disruptions and heightened regulatory scrutiny, the role of the top pharmaceutical API manufacturer has taken on ...

BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) is one of the top gene therapy stocks to buy according to hedge funds. On February 25, Bernstein lifted the price target on BioMarin Pharmaceutical Inc.

SpyGlass Pharma, Inc. (Nasdaq: SGP) ('SpyGlass Pharma”), a late-stage biopharmaceutical company, today announced that members of the executive management team will host 1x1 meetings at the Jefferies ...

The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now… and Teva Pharmaceutical Industries wasn’t one of them. The 10 stocks that ...